Navigation Links
Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
Date:2/22/2011

VANCOUVER, British Columbia, Feb. 22, 2011 /PRNewswire/ -- Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the IN3 West Investment in Innovation Conference on Thursday, February 24 at 11:05 AM PST. The conference is being held at the Venetian Hotel in Las Vegas.

Dr. Rewcastle will provide an overview of Enox's technology and its ability to embed nitric oxide into polymer medical devices rendering them antimicrobial. He will also review recently published independent data that shows that ionic silver coatings for medical devices are not as effective as hoped.

"There is a very significant clinical need for an effective non-antibiotic treatment to render medical devices antimicrobial," said Rewcastle. "Each year in the United States alone, hospital acquired infections kill hundreds of thousands of patients and cost the health care system tens of billions of dollars. Silver coatings were hoped to be an answer to increasing antibiotic but, based on recent publications, this does not appear to be the case. Our nitric oxide technology is uniquely positioned to answer this critical need of all healthcare systems worldwide."

"The IN3 West Conference is an ideal venue for Enox to present at," continued Rewcastle. "The participants consist of both venture capitalists and larger companies seeking to partner with emerging technologies. I am looking forward to the meeting and expect a very positive response."About Enox Biopharma Inc.Enox Biopharma, Inc. is an emerging biotechnology company with proprietary technology that embeds nitric oxide (NO) into polymer medical devices. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes, tympanostomy tubes and cosmetic implants. With the current CMS non-coverage of certain nosocomial infections the financial burden of these infections has shifted to hospitals who are desperately seeking ways to reduce infection rates. By utilizing NO, part of the human body's innate immune system, Enox Biopharma is improving existing medical devices by making them antimicrobial.

Forward Looking Information

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on management's good faith views and expectations when made. Forward-looking statements are inherently subject to known and unknown risks and uncertainties which, in the case of the company, include raising adequate capital to continue operations, technology and product development uncertainties, and competition. Actual financial results of the company may differ, perhaps materially, from those discussed in the forward-looking statements. The company is not obligated, and does not undertake, to update its forward-looking statements or comment on the differences that may develop between its statements and actual results. Readers are encouraged to refer to the recent public filings of the company to further ascertain the risks associated with the forward-looking statements. Readers are urged not to place undue reliance upon such statements.For more information, please contact:John C. Rewcastle, Ph.D., CEO orItamar David, CFOEnoxBiopharma, Inc.604.637.9744 phone888.224.7259 faxinfo@enoxbiopharma.comwww.enoxbiopharma.com
'/>"/>

SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
2. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
3. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
4. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
5. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
6. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
7. Plato BioPharma, Inc Appoints New Board Member
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... and PUNE, India , January ... by Allied Market Research, titled, "Vital Signs Monitoring Devices Market ... Forecast, 2014-2022", projects that the global vital signs monitoring devices ... expected to reach $5,491 million by 2022, growing at a ... America was the leading regional market in global ...
(Date:1/16/2017)... Oregon and PUNE, India , January 16, 2017 ... Research, titled, "Antioxidants Market by Type - Global Opportunity Analysis and Industry Forecast, ... is expected to reach $4,531 million by 2022, registering a CAGR of 6.42% ... for more than one-third share of the global volume in 2015. ... ...
(Date:1/16/2017)... 16, 2017  Dovetail Genomics today announced the commercial ... service, which yields chromosome-scale genome assemblies. The service is ... workshop on Jan. 17 at the Plant & Animal ... . "We are thrilled to be ... our Dovetail Hi-C offering," said Todd Dickinson , ...
Breaking Medicine Technology:
(Date:1/16/2017)... GA (PRWEB) , ... January 16, 2017 , ... ... to announce their recent partnership with an innovator in the wheelchair accessibility industry, ... to motivate their dealer salespeople to sell wheelchair accessible vehicles. With this new ...
(Date:1/16/2017)... ... ... One thing common to all types of cancer is that it’s a ... money spent screening for and treating cancer in the United States is estimated to ... than in any other country that has an advanced healthcare system, sometimes spending as ...
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and ... that strives to better communities around the world by offering the Gensuite team ... the opportunity for team members to become involved in a cause that is ...
(Date:1/15/2017)... ... 14, 2017 , ... Wondering where to go this Valentine's Day? Well, there ... for a romantic, lobster feast in the comfort of your own home. Lobster Gram ... dinners will be featured until February 15th, 2017. , Romantic Dinner one is ...
(Date:1/14/2017)... ... January 14, 2017 , ... AgileMinder develops innovative products and services ... Scale is now available on Apple as a fun, free emoji sticker pack for ... one of the ten color coded values on The Emoji Scale. , On ...
Breaking Medicine News(10 mins):